Academia.edu no longer supports Internet Explorer.
To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to upgrade your browser .
Enter the email address you signed up with and we'll email you a reset link.
- We're Hiring!
- Help Center
PROJECT PROPOSAL CERVICAL CANCER SCREENING T VENGESAI
Related Papers
Tirivanhu Chipfuwa
Fred Nuwaha
Fresier Maseko
International journal of public health
Nestory Masalu
To report the results of a pilot study for a service for cervical cancer screening and diagnosis in north-western Tanzania. The pilot study was launched in 2012 after a community-level information campaign. Women aged 15-64 years were encouraged to attend the district health centres. Attendees were offered a conventional Pap smear and a visual inspection of the cervix with acetic acid (VIA). The first 2500 women were evaluated. A total of 164 women (detection rate 70.0/1000) were diagnosed with high-grade cervical intraepithelial neoplasia and invasive cervical cancer. The performance of VIA was comparable to that of Pap smear. The district of residence, a history of untreated sexually transmitted disease, an HIV-negative status (inverse association), and parity were independently associated with the detected prevalence of disease. The probability of invasive versus preinvasive disease was lower in HIV-positive women and in women practicing breast self-examination. The diagnostic pr...
PLOS global public health
John M U K U K A Musonda
Cogent Social Sciences
elimon nyamambi
BMC Public Health
TWAMBILIRE PHIRI
Texila International Journal of Public Health
Texila International Journal , Dingase Mvula
Women living with Human Immunodeficiency Virus (WLHIV) have a higher risk of developing cervical cancer due to their immune-compromised state. Cervical cancer screening leads to early detection and treatment. The aim of the study was to determine the knowledge, attitude, and practices of cervical cancer screening among women infected with HIV in Kasenengwa District, Eastern Province, Zambia. A descriptive cross-sectional study design using a semi-structured questionnaire was used to collect data from 266 WLHIV. Basic descriptive statistics were done using SPSS version 23.0. Almost two-thirds (62.7%) of the 266 WLHIV in the study had adequate knowledge about cervical cancer screening. Almost three-fifths of the respondents (57.1%) had a negative attitude toward cervical cancer screening. The majority (78.2%) had been counselled by healthcare workers on cervical cancer screening with good emotional support from family members (72.9%). About twothirds (68.4%) of the respondents had been screened for cervical cancer. Most women indicated that they didn't have access to cervical cancer screening services because they did not know where to go (61.5%) and distant screening sites (56.3%) WLHIV in the study had adequate knowledge, but unfavorable attitude towards cervical cancer screening, while two-thirds had been screened for cervical cancer. Accessibility to screening sites was poor. More education and sensitization are needed in the district to eliminate misconceptions about cervical cancer screening, which may influence uptake.
Marianne Calnan
Determinants of Cervical Cancer Screening in HIV-Positive Young Women in Swaziland by Marianne Calnan MPH, Manchester University, 2012 MMed Internal Medicine, Makerere University, 2005 MBCHB, Mbarara University of Science and Technology, 1998 Doctoral Study Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Public Health Walden University February 2019 Abstract In Swaziland, cases of cervical cancer among Human Immunodeficiency Virus (HIV)positive adolescent girls and young women (AGYW) are increasing, but there is low uptake of cervical cancer screening. This study was conducted using the systems thinking theory to explore the relationships between the uptake of cervical cancer screening among HIVpositive AGYW in Swaziland and the availability of trained health providers, cervical screening services, and the provision of referrals for cervical screening. The study also investigated any differences in uptake of cervical screening based on age group. For...
RELATED PAPERS
Masahiro Sakai
Willem Ombelet
Solbon Lkhasaranov
Jennifer Gagnon
Annals of the rheumatic diseases
Xavier Estivill
Daria Oreshina
Annas Miftakhuddin
Tidsskrift for Arbejdsliv
Arne Helgesen
Harry van Lenthe
International Journal Of Community Medicine And Public Health
Abhay Srivastava
Damir Juras
Transportation Research Record: Journal of the Transportation Research Board
Imad L . Al-Qadi
IJAERS Journal
IOP Conference Series: Materials Science and Engineering
Busisiwe Mfusi
Nama Sepatu Kets
Trilhas formativas: experiências e propostas para formação continuada e em serviço de formadores e docentes na era digital
Renata Kelly da Silva
Ica Lestari
Afaf Alharthi
International Journal of Innovation and Applied Studies
Franck Gnamba
Animal Husbandry, Dairy and Veterinary Science
Akbar Nikkhah
Miguel Oliveira
The Proceedings of the Annual Convention of the Japanese Psychological Association
Chika Harada
Health Science Reports
Dereje Zewdu
Marco Hostettler, Anja Buhlke, Clara Drummer, Lea Emmenegger, Johannes Reich, Corinne Stäheli (eds.), The 3 Dimensions of Digitalised Archaeology
Christian Horn , Johan Ling
The Journal of Physical Chemistry C
David Waldeck
- We're Hiring!
- Help Center
- Find new research papers in:
- Health Sciences
- Earth Sciences
- Cognitive Science
- Mathematics
- Computer Science
- Academia ©2024
- Limited Submission Opportunity: 2024 V Foundation Pediatric Cancer Research Awards
Media Inquiries
- 615-322-6397 Email
Latest Stories
- Pietenpol to receive American Society of Clinical Oncology’s highest honor
- NERL and Springer Nature sign new three-year open publishing agreement
Apr 17, 2024, 9:45 AM
Applications due April 25
This is a joint competition for VU and VUMC investigators. All investigators should follow these instructions .
Vanderbilt (VU and VUMC, collaboratively) may choose one nominee for the Pediatric Cancer Research Grant Program. The single nominee may apply in either the V Scholar or the Translational program type for support.
Note that internal competitions for the V Foundation awards (V Scholar, Translational) focused on adult cancers have already closed for 2024.
- Translational projects should move a novel strategy from the laboratory into a human clinical trial or use specimens from a clinical trial to develop biomarkers or mechanisms. The research should apply in some direct way to human beings within the time frame of less than 3 years from the end of the grant. If biomarker research is undertaken, a validation set or independent clinical trial is essential. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new clinical trial.
- This award is specifically for pediatric cancer research that falls into preclinical/translational research as described above. Please note that research areas not included in this scope are epidemiology, behavioral science, and health services research.
- This award is specifically for pediatric cancer research. Please note that research areas not included in this scope are epidemiology, behavioral science, and health services research.
Eligibility
- Exceptions may be made for non-tenure track faculty holding Assistant, Associate, or Full Professor positions. Please reach out to [email protected] if you are interested in applying but are not tenure-track.
- Applicants must be either US citizens or have a legal permit (temporary or permanent) to work in the US.
- Non-promotable, adjunct, affiliated, temporary, part-time or acting faculty positions are not eligible for the V Scholar award.
- Extensions may be given on a case-by-case basis .
- Clinical scientists are eligible if their department can demonstrate that it will fully support the research applicant (e.g., dedicated lab space, start-up funds, dedicated research time).
- For M.D., a minimum of one year is acceptable if only one year is required for their specialty.
- Applicant must be a U.S. citizen or permanent legal resident in the U.S.
- Applicants must NOT have accepted or received notification of an R01 award by this nomination due date.
- Applicants must NOT have accepted or received award notification of any peer-reviewed, non-mentored single grant that totals or exceeds $750k in total direct funding at ANY point in their professional career. This calculation should exclude indirect costs.
- The V Scholar award is intended to support research to leverage these larger awards; so, the nominee should not have already received such awards.
- View the 2024 V Scholar Eligibility: Are they Eligible handout for additional guidance.
Internal Application Process
Anyone interested in being considered as Vanderbilt’s nominee for either of the Pediatric Awards above must submit the following (in PDF format) to [email protected] by 11:59 p.m. on April 25, 202 4. Late applications will not be considered.
- Brief (2 page maximum) research plan including summary budget;
- V Scholar award does not allow indirect costs. V Scholar letters must acknowledge that this grant does not allow indirect costs. This statement can be used/modified within the letter: “The Department recognizes that this grant does not allow indirect costs and will commit to covering any associated indirect costs per applicable institutional/school policy.” Consult [email protected] for further guidance.
- Translational award allows 10% indirect costs; indirect cost statement is not required.
- NIH Biosketch or 5-page CV
- Please fill out the Grant Awards table and any “Notes and Remarks.”
- Other information and signatures not required for internal selection process.
Submissions should reference the award type (Translational Research Award or V Scholar) in the subject line of the email.
A short nomination package for Vanderbilt’s selected candidate will be submitted to the V Foundation by May 10, 2024. The candidate will then receive an invitation to submit a full application, due June 17, 2024.
Email [email protected] if you have any questions about the program, foundation or internal review process.
Keep Reading
Limited Submission Opportunity: 2024 V Foundation Women Scientists Innovation Award for Cancer Research
Limited Submission Opportunity: 2024 Pediatric Cancer Research Foundation Grants
Limited Submission Opportunity: 2024 St. Baldrick’s Foundation Research Grants
Explore story topics.
- Research Blog
- limited submission opportunity
- Office of the Provost
An official website of the United States government
Here’s how you know
Official websites use .gov A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
JavaScript appears to be disabled on this computer. Please click here to see any active alerts .
Final Rule to Strengthen Standards for Synthetic Organic Chemical Plants and Polymers and Resins Plants
April 9, 2024, the U.S. Environmental Protection Agency (EPA) announced a set of final rules that will significantly reduce emissions of toxic air pollution from chemical plants, including the potent air toxics ethylene oxide (EtO) and chloroprene. The reductions dramatically reduce the number of people with elevated air toxics-related cancer risks in communities surrounding the plants that use those two chemicals, especially communities historically overburdened by air toxics pollution.
Regulatory Documents
- Final Rule (prepublication version) (pdf) (5 MB)
- Regulatory Impact Analysis for the Final Rule (pdf) (1.3 MB)
Fact Sheets, Infographic and Presentation
- Fact Sheet: Overview of the Final Rule (pdf) (287.6 KB)
- Fact Sheet: Key Things to Know About the Final Rule (pdf) (192.9 KB)
- Infographic: EPA’s Air Toxics Rules for the Synthetic Organic Chemical Manufacturing and Polymers & Resins Industries (pdf) (54.7 MB)
- Overview Presentation: EPA's Final Rules for the Synthetic Organic Chemical Manufacturing Industry and Group I & II Polymers and Resins Industry (pdf) (711.3 KB)
Additional Documents
- List of facilities covered by National Emissions Standards for Hazardous Air Pollutants for Synthetic Organic Chemical Plants and Group I and Group II Polymers and Resins Plants
Documents from Proposal
- Proposed Rule
- Regulatory Impact Analysis for the Proposal
- Fact Sheet on EPA's Community Risk Assessment and Risk Based Demographic Assessment
Web Pages for Individual Air Toxics Rules Included in the Final Action
Synthetic Organic Chemical Manufacturing Industry: Organic National Emission Standards for Hazardous Air Pollutants (NESHAP) - 40 CFR 63 Subparts F,G,H,I
Group I Polymers and Resins: National Emission Standards for Hazardous Air Pollutants (NESHAP)
Group 2 Polymers and Resins: Epoxy Resins Production and Non-Nylon Polyamides: National Emission Standards for Hazardous Air Pollutants (NESHAP)
- Ethylene Oxide (EtO) Home
- EPA Actions To Reduce Risk
- Our Current Understanding
- EtO Risk and Your Health
- Addressing and Learning About EtO
- EtO Community Engagement
- Federal Partnerships on EtO
- EtO Additional Questions
The Federal Register
The daily journal of the united states government, request access.
Due to aggressive automated scraping of FederalRegister.gov and eCFR.gov, programmatic access to these sites is limited to access to our extensive developer APIs.
If you are human user receiving this message, we can add your IP address to a set of IPs that can access FederalRegister.gov & eCFR.gov; complete the CAPTCHA (bot test) below and click "Request Access". This process will be necessary for each IP address you wish to access the site from, requests are valid for approximately one quarter (three months) after which the process may need to be repeated.
An official website of the United States government.
If you want to request a wider IP range, first request access for your current IP, and then use the "Site Feedback" button found in the lower left-hand side to make the request.
IMAGES
VIDEO
COMMENTS
prevalent cases of cancer and about 35,000 new cases are added to this every year. Based on the. (18.5%) it ranks second to cervical cancer. The burden of breast cancer is increasing in both. rate ...
RESEARCH PROPOSAL Hypothesis: Cancer associated fibroblasts cause drug resistance in mutant KRAS-driven colon and lung cancers by altering signal transduction in cancer cells. Establishing an assay to determine drug resistance associated with co-culture of cancer cells with cancer- associated fibroblasts ...
More than half a million of the world's women died from breast cancer in 2012, making it one of the leading (BC) causes of cancer-related deaths in women across the world (Ferlay et al., 2015). The phosphatidylinositol 3-kinase (PI3K)/Akt pathway represents a complex signalling network that integrates numerous upstream stimuli to
project will benefit from the programme of research in Harrington's CRUK Programme Grant that will specifically address the phenotypic and therapeutic effects of -radiation combinations in head and neck cancer. Reagents IO acquired for that programme will be used in this project (e.g. TLR7/8 and STING agonists).
The resources below are provided as templates and guides for those preparing extramural proposals. If you have any questions regarding these resources, please feel free to contact us at [email protected] Budget Resources UF Division of Sponsored Programs Budget Guidelines UF Fringe Rates Boilerplate Language Facilities and Other Resources
R03 Small Research Grant. Small Research Grants (R03s) provide research support specifically limited in time and amount for studies in categorical program areas. Small research grants provide flexibility for initiating studies that are generally for preliminary short-term projects. These grants are non-renewable.
colonoscopy within 18 months of a curative resection for colorectal cancer. Functions 1. Provide reviewers with a clear picture of what you plan to accomplish. 2. Show the reviewers that you have a clear picture of what you want to accomplish. 3. Form the foundation for the rest of the proposal. Writing an Effective Research Proposal 11
Request for Proposals: 2024 LCRF Leading Edge Research Grant Program 1. Program Summary Lung cancer continues to be the number one cause of cancer deaths worldwide, accounting for an estimated 127,070 deaths annually in the United States alone1. Despite being the most common cancer killer for both men
graduates have a true understanding of multidisciplinary academic / clinical / industry cancer research, while at the same time, progressing our anti-cancer drugs towards the clinic in the interest of cancer patients. Background and Rationale: In Ireland an average of 30,000 new cases of cancer are diagnosed each year, resulting in more than
The student who will be conducting this research will be given support by a supervisory team with both industrial and academic expertise in both medicinal and synthetic chemistry, chemoproteomics and cancer biology. The student will also be mainly placed in the 4th Group of the Medicinal Chemistry team, along with Dr. Strauss Meyer.
survivors of cancer diagnosed in the post-infancy years. 4. ANALYSIS FRAMEWORK . a) Participant population: Survivors of cancer in childhood (< 18 yrs of age at time of onset or diagnosis of cancer) defined into specific ages of diagnosis (0 to 2, 3 to 6 years). b) Comparison groups: Survivors of cancer diagnosed at infancy (0-2 years) versus ...
NCI, the largest funder of cancer research in the . world, is the engine that drives progress. Institutions . across the cancer research community—such as the . 72 NCI-Designated Cancer Centers, 2,200 National Clinical Trials Network sites, and 46 NCORP network sites with more than 1,000 practices nationwide—
Research Proposal Self-Management and. Commitment for Cancer P atients. Sitvast J*. Department of Applied Sciences, Netherlands. Introduction. In the Netherlands a new concept of health has been ...
PDF | Breast cancer is the most common diagnosed malignancy in women worldwide (22%) and in India (18.5%) it ranks second to cervical cancer. ... Research Proposal PDF Available. Breast Cancer ...
PROFESSIONAL JUDGMENT BUDGET PROPOSAL FOR FISCAL YEAR 2022. * The increase of $1,170 million includes an inflation adjustment and $860 million for additional cancer research in six major focus areas. † This adjustment includes inflation for the 2 years between FY 2020 and FY 2022.
Almost three-fifths of the respondents (57.1%) had a negative attitude toward cervical cancer screening. The majority (78.2%) had been counselled by healthcare workers on cervical cancer screening with good emotional support from family members (72.9%). About twothirds (68.4%) of the respondents had been screened for cervical cancer.
his proposal for a significant budget increase in FY 2024 is designed to capitalize on important scientific opportunities in pursuit of the goal to end cancer as we know it for all people. These opportunities include. the exceptional ideas being put forth by the cancer research community, particularly in the explosion of R01 applications in ...
ABSTRACT. x. Cervical cancer is a major global health problem, it is the fourth most common cancer among women globally, with estimated 570,000. new cases and 311,000 deaths worldwide in 2018. W ...
The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016;11:39-51.
The V Foundation seeks to support translational research projects within the scope of pediatric cancer research. The Translational Research Award is a $800,000 grant awarded in four annual ...
The FY 2023 budget proposal would enable NCI to increase R01 paylines to the 13th percentile, allowing NCI to fund a greater number of meritorious applications. Robust and sustained investments are needed to achieve the 15th percentile R01 payline by FY 2025. NCI is seizing new opportunities in cancer research and building on progress in ...
India. Abstract. Cervical cancer develops in a woman's cervix (the entrance to the uterus from the vagina). Almost all cervical cancer cases (99%) are linke d to infection with high-risk human ...
The reductions dramatically reduce the number of people with elevated air toxics-related cancer risks in communities surrounding the plants that use those two chemicals, especially communities historically overburdened by air toxics pollution. Regulatory Documents. Final Rule (prepublication version) (pdf) (5 MB)
Federal Register/Vol. 89, No. 74/Tuesday, April 16, 2024/Proposed Rules 26837 4 Turbine NESHAP Unit List—Updated October 2023. Docket ID No. EPA-HQ-OAR-2020-0408. 5 Petition to Delist Two Subcategories of Combustion Turbines. Docket ID No. EPA-HQ- OAR-2003-0189-0014. 6 As stated previously, the EPA has determined that the current petition to delist the Stationary
NCI is committed to investigator- initiated research . The FY 2023 budget proposal would enable NCI to increase R01 paylines. to the 13th percentile, allowing NCI to fund a greater number of meritorious applications. Robust and sustained investments are needed to achieve the 15th percentile R01 payline by FY 2025.
Proposal for cervical cancer screening in the era of HPV. vaccination. Yung-T aek Ouh, Jae Kwan Lee. Department of Obstetrics and Gynecology, Guro Hospital, Korea University College of Medicine ...
NCI PROFESSIONAL JUDGMENT BUDGET PROPOSAL. NCI's proposal for a significant budget increase in fiscal year (FY) 2024 is designed to capitalize on important scientific opportunities in pursuit of the goal to end cancer as we know it for all people. These opportunities include.
This PDF is the current document as it appeared on Public Inspection on 04/15/2024 at 8:45 am. It was viewed 114 times while on Public Inspection. If you are using public inspection listings for legal research, you should verify the contents of the documents against a final, official edition of the Federal Register.